Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing rapidly.

There's a good reason for this shift: The tech part of TechBio focuses on machine learning and artificial intelligence (AI). Nearly every industry is undergoing an AI-fueled transformation. Biopharmaceutical development is no exception.

That's great news for Recursion. Its shares have plunged more than 70% since the company's initial public offering (IPO) in 2021. But the potential for its technology and pipeline have arguably never looked as promising. Can Recursion Pharmaceuticals stock double in five years? Here's what it would take.

Continue reading

Source Fool.com